Medicus Pharma (NASDAQ:MDCX) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Medicus Pharma (NASDAQ:MDCX) to a strong sell rating in a research report report published on Saturday,Wall Street Zen reports.

MDCX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a report on Friday, October 2nd. Alliance Global Partners restated a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $450.00.

Medicus Pharma Trading Down 18.5%

Shares of Medicus Pharma stock opened at $2.65 on Friday. Medicus Pharma has a 52 week low of $2.55 and a 52 week high of $139.00. The stock has a market cap of $3.34 million, a PE ratio of -0.02 and a beta of 0.30. The company’s 50-day moving average price is $9.38 and its two-hundred day moving average price is $14.90.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($10.50) earnings per share for the quarter, missing the consensus estimate of ($6.38) by ($4.12). On average, equities analysts predict that Medicus Pharma will post -36.25 EPS for the current fiscal year.

Institutional Trading of Medicus Pharma

A hedge fund recently bought a new position in Medicus Pharma stock. Sterling Investment Advisors Ltd. bought a new position in Medicus Pharma Ltd (NASDAQ:MDCX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 100,000 shares of the company’s stock, valued at approximately $45,000. Sterling Investment Advisors Ltd. owned 0.16% of Medicus Pharma at the end of the most recent reporting period.

About Medicus Pharma

Medicus Pharma Ltd. is a life sciences company focused on acquiring, developing and commercializing innovative therapeutic and medical device technologies. Its activities are centered primarily on wound care, dermatology and related areas of medical treatment.

The company’s portfolio includes Natrox® Oxygen Wound Therapy, a device designed to deliver continuous topical oxygen to the wound site. The technology is intended to support the treatment of chronic and hard-to-heal wounds and may be used in clinical and home-care settings, subject to applicable regulatory approvals.

Medicus Pharma serves healthcare markets through the commercialization of its technologies and partnerships with medical professionals and distribution networks.